Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): Optimization of prodrug activating capacity

Pharmaceutical Research

Volumn 13, Issue 4, 1996, Pages 604-610

  Vingerhoeds, Monique H ^a   Haisma, Hidde J ^b   Belliot, Sheila O ^a   Smit, Roefke H P ^a   Crommelin, Daan J A ^a   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADEPT; Antibody directed enzyme prodrug therapy; Liposomes; Monoclonal antibody; Targeted drug delivery

Indexed keywords

BETA GLUCURONIDASE; CYTOSTATIC AGENT; DAUNORUBICIN; DRUG CARRIER; IMINOTHIOL; IMMUNOLIPOSOME; PRODRUG; THIOL GROUP;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DENSITY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IONIC STRENGTH; OVARY CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE CHARGE; TARGET CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; BINDING SITES; CARCINOMA; CROSS-LINKING REAGENTS; DAUNORUBICIN; DRUG CARRIERS; FEMALE; GLUCURONATES; GLUCURONIDASE; HUMANS; IMIDOESTERS; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; MICE; OVARIAN NEOPLASMS; PRODRUGS; SUCCINIMIDES; SULFIDES; TUMOR CELLS, CULTURED;

EID: 0029922230     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016010524510     Document Type: Article

References (15)

1. P. D. Senter, P. M. Wallace, H. P. Svensson, V. M. Vrudhula, D. E. Kerr, I. Hellström and K. E. Hellström. Generation of cytotoxic agents by targeted enzymes. Bioconj. Chem. 4:3-9 (1993).
2. M. P. Deonarain and A. A. Epenetos. Targeting enzymes for cancer therapy: old enzymes in new roles. Br. J. Cancer 70:786-794 (1994).
3. K. D. Bagshawe, C. J. Springer, F. Searle, P. Antoniw, S. K. Sharma, R. G. Melton and R. F. Sherwood. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58:700-703 (1988).
4. H. J. Haisma, E. Boven, M. van Muijen, J. de Jong, W. J. F. van der Vijgh and H. M. Pinedo. A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66:474-478 (1992).
5. K. D. Bagshawe, S. K. Sharma, C. J. Springer and P. Antoniw. Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting 1:17-29 (1995).
6. M. H. Vingerhoeds, H. J. Haisma, M. van Muijen, R. B. J. van de Rijt, D. J. A. Crommelin and G. Storm. A new application for liposomes in cancer therapy: immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett. 336:485-490 (1993).
7. U. K. Nässander, P. A. Steerenberg, W. H. De Jong, W. O. W. M. van Overveld, C. M. E. te Boekhorst, L. G. Poels, P. H. K. Jap and G. Storm. Design of immunoliposomes directed against human ovarian carcinoma. Biochim. Biophys. Acta 1235:126-139 (1995).
8. R. J. S. Duncan, P. D. Weston and R. Wrigglesworth. A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immuno-assay. Anal. Biochem. 132:68-73 (1983).
9. C. H. Fiske and Y. Subbarow. The colorimetric determination of phosphorus. J. Biol. Chem. 66:375-400 (1925).
10. D. Wessel and U. I. Flügge. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 138:141-143 (1984).
11. T. C. Hamilton, R. C. Young, W. M. McKoy, K. R. Grotzinger, J. A. Green, E. W. Chu, J. Whang-Penn, A. M. Rogan, W. R. Green and R. F. Ozols. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43:5379-5389 (1983).
12. R. G. G. Leenders, K. A. A. Gerrits, R. Ruijtenbeek, H. W. Scheeren, H. J. Haisma and E. Boven. β-Glucuronyl carbamate based pro-moieties designed for prodrugs in ADEPT. Tetrahedon Lett. 36:1701-1704 (1995).
13. J. L. M. Heeremans, R. Prevost, P. Los, C. Kluft and D. J. A. Crommelin. Fibrin binding glu-plasminogen coated liposomes in vitro. Thromb. Haemostas: 75:1 134-139 (1996).
14. J. Connor, S. Sullivan and L. Huang. Monoclonal antibody and liposomes. Pharmacol. Ther. 28:341-365 (1985).
15. H. J. Haisma, M. van Muijen, H. M. Pinedo, and E. Boven. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys. 24/25:185-192 (1994).